Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Effect of the Kv7-channel Opener Flupirtine on the Excitability of Human Peripheral Myelinated Axons in Vivo
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.
Genzyme’s Lemtrada Approved by the FDA
Drug Safety Labeling Changes
Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review.
Fatal Acute Myeloid Leukemia With 11q23 MLL Gene Rearrangement Following Mitoxantrone Treatment in a Case of Childhood-onset Multiple Sclerosis.
Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations
Onset of multiple sclerosis before adulthood leads to failure of age-expected brain growth.
Genzyme receives positive CHMP opinion in the European Union for once-daily, oral AUBAGIO® to treat relapsing-remitting multiple sclerosis
Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy.
[Results of a comparative clinical trial of the Russian Β - interferon-1b bioanalogue (infibeta)].
Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration.
Synthetic Biologics Reports Results of Independent Third Party Evaluations of Trimesta™ Data from Investigator-Sponsored Phase 2 Clinical Trial for Relapsing-Remitting Multiple Sclerosis
New multiple sclerosis phenotypic classification.
Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis.
Impact of cladribine therapy on changes in circulating dendritic cell subsets, T cells and B cells in patients with multiple sclerosis.
Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research.
Novel therapies for memory cells in autoimmune diseases.
Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study.
IgE-Mediated Allergic Reactions after the First Administration of Glatiramer Acetate in Patients with Multiple Sclerosis.
Pregnancy outcomes in patients exposed to interferon beta-1b.
Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome.
Impact of MS during the critical window of brain development.
Selective inhibition of the mitochondrial permeability transition pore protects against neuro-degeneration in experimental multiple sclerosis.
Multiple sclerosis: risk factors, prodromes, and potential causal pathways.

Pages